What does this research mean for the field?

XR300 is a highly specific nonpeptide GPIIb/IIIa antagonist that demonstrates potent intravenous and oral antithrombotic efficacy in preventing arterial thrombosis. Novelty: ClaimNovelty.NOVEL_FINDING. Consensus alignment: ConsensusAlignment.NEUTRAL.

March 1, 1998Journal of Cardiovascular Pharmacology

Intravenous and Oral Antiplatelet/Antithrombotic Efficacy and Specificity of XR300, a Novel Nonpeptide Platelet GPIIb/IIIa Antagonist

View Full Paper

Ask AI

Bookmark

Why the study?

Does XR300 prevent thrombosis and inhibit platelet aggregation in preclinical models?

Population

Human platelets and mongrel dogs

Design

Preclinical

Authors

SMShaker A. MousaUniversity of North Carolina at Chapel Hill MFMark S. ForsytheDuPont (United States)JWJohn WityakCHDI Foundation

Discussion

Member takes

Implication

XR300 shows potent preclinical antithrombotic activity; leaves open translation to human trials.

Structured PICO

Does XR300 prevent thrombosis and inhibit platelet aggregation in preclinical models?

Population

Human platelets (in vitro) and mongrel dogs (in vivo carotid or femoral artery thrombosis models induced electrolytically or by mechanical injury with stenosis)

Intervention

XR300 (intravenous 0.5-1.0 mg/kg or oral 1.0-2.0 mg/kg) and its active form XR299

Outcome

Inhibition of platelet aggregation, fibrinogen binding, and prevention of occlusive thrombosis or cyclic flow reductionsurrogate

XR300 is a novel, specific nonpeptide GPIIb/IIIa antagonist with potent intravenous and oral antiplatelet and antithrombotic effects in preclinical models.

Cite This Study

Mousa et al. (1998) studied this question.

synapsesocial.com/papers/6a1bc2dd69a4af5b15a8f3bc https://doi.org/10.1097/00005344-199803000-00016

Topics

Dual antiplatelet therapy

View Full Paper

Ask AI

Bookmark

Intravenous and Oral Antiplatelet/Antithrombotic Efficacy and Specificity of XR300, a Novel Nonpeptide Platelet GPIIb/IIIa Antagonist

Discussion

Member takes

Implication

Structured PICO

Cite This Study

Topics

Intravenous and Oral Antiplatelet/Antithrombotic Efficacy and Specificity of XR300, a Novel Nonpeptide Platelet GPIIb/IIIa Antagonist

Discussion

Member takes

Implication

Structured PICO

Cite This Study

Also Consider

Topics

Also Consider